Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-randomized, Open, Single-dose, Parallel Designed Clinical Study to Evaluate Safety and Pharmacokinetic Characteristics After Oral Administration of Besivo® in Patients With Renal Impairment and Healthy Adult Volunteers

NCT04249908 is registered in ClinicalTrials.gov with IlDong Pharmaceutical Co Ltd as lead sponsor.

NCT NCT04249908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04249908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-randomized, Open, Single-dose, Parallel Designed Clinical Study to Evaluate Safety and Pharmacokinetic Characteristics After Oral Administration of Besivo® in Patients With Renal Impairment and Healthy Adult Volunteers
Lead sponsor
IlDong Pharmaceutical Co Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
February 13, 2020
Completion date
April 30, 2021
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment